Sopharma reports 43 percent sales growth: what it means for Sopharma stock

Published on 10/01/2026 at 16:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Exports rose 68 percent through August 2026 versus 3 percent domestically. Sopharma stock is valued above EUR 1.24 billion on September 1, 2026.

Sopharma, BG11SOSOBT18, Illustration mit AI erstellt.

Sopharma (ISIN BG11SOSOBT18) reported 43 percent sales growth from January through August 2026, with export sales rising 68 percent and domestic sales increasing 3 percent. The figures came in a September 21, 2026 release covered by MarketScreener. The comparison points to exports as the main growth engine during the first eight months.

Exports drive 43 percent growth

Sopharma's August sales rose 1 percent year over year, but the geographic split was uneven. Domestic sales fell 3 percent in August, while export sales rose 4 percent, according to the September 21 release carried by MarketScreener.

The year-to-date figures are stronger than the single-month result: total sales increased 43 percent, export sales advanced 68 percent and domestic sales grew 3 percent. That gap makes international demand the central operating variable for the stock story.

First-half profit adds support

Sopharma reported revenue of more than EUR 730 million in the first half of 2026, up more than 11 percent from the first half of 2025. Net profit rose 35 percent to more than EUR 52 million, according to the consolidated financial report cited by bne IntelliNews on September 1, 2026.

The profit increase is important because the August sales release contains revenue data rather than a full earnings statement. Together, the two updates show both the scale of first-half operations and the continued sales momentum into the third quarter.

What 43 percent growth means

For Sopharma stock, the export contribution matters more than the 1 percent August headline alone. A 68 percent increase in export sales compared with 3 percent domestic growth creates a clear operating contrast, while the 35 percent first-half net profit increase provides a second measure of performance.

On September 1, 2026, Sopharma's market capitalization exceeded EUR 1.24 billion after rising 20 percent over the previous month, according to bne IntelliNews. The company thereby became the largest listed company on the Bulgarian Stock Exchange by market capitalization.

Market value and listing

Sopharma is listed on the Bulgarian Stock Exchange under ticker SFA and is included in the SOFIX index. Its market capitalization exceeded EUR 1.24 billion on September 1, 2026, while first-half revenue exceeded EUR 730 million and net profit exceeded EUR 52 million.